However, the mean changes from baseline on the pulse rate hardly changed in the IM haloperidol injection group (Table 2). The systolic blood pressure increased significantly from baseline in the IM olanzapine injection group, but the mean change from baseline on the systolic blood pressure hardly changed in the IM haloperidol injection group. Inhibitors,research,lifescience,medical The glucose level (mg/dl) decreased significantly from baseline in both the IM olanzapine injection group and the IM haloperidol injection group, but no significant
differences were seen between the two groups (Table 2). The incidence of adverse events associated with injection site RO4929097 nmr reactions in both groups were 16.7% (2/12) in the IM olanzapine injection group and 18.2% (2/11) in the IM haloperidol injection group. All these adverse events were injection site pain; no redness, swelling or induration were observed. The most frequent adverse events in both groups are shown in Table 3. Table 3. Adverse events. The injections were administered at the same time in each group. The average medication doses of both groups were 7.7 ± 2.5 (mg) with Inhibitors,research,lifescience,medical the IM olanzapine Inhibitors,research,lifescience,medical injection group and 4.6 ± 1.0 (mg) with the IM haloperidol injection group. Discussion In this study, we compared the efficacy and safety of IM olanzapine and IM haloperidol in agitated elderly patients with schizophrenia at 2 hours postdose. The results of this study not only show that olanzapine has a different pharmacological
profile to haloperidol, but also suggest that IM olanzapine can, thanks to its pharmacokinetics, afford patients a more rapid sedative effect and more rapid improvement in impulse control and excitement than IM haloperidol. However, since both drugs possess affinity for dopamine (D2) receptors, Inhibitors,research,lifescience,medical no significant difference was found between the two groups in improvement in positive symptoms. Inhibitors,research,lifescience,medical The results were therefore consistent with the results of our previous research and the results of other studies conducted in the past [Centorrino et al. 2007; MacDonald et al. 2012; San
et al. 2006; Wright et al. 2001]. The results suggested that IM olanzapine prevented the emergence of drug-induced extrapyramidal symptoms 4-Aminobutyrate aminotransferase in the elderly compared with IM haloperidol. The findings also are consistent with those of previously conducted research [Perrin et al. 2012; Satterthwaite et al. 2008]. In the elderly, arrhythmias result in symptoms including dizziness, palpitations and shortness of breath that are a contributing factor for a poor prognosis. Although the results of this study showed that IM olanzapine resulted in a decrease in pulse rate, it remained within the range of normal in all the subjects. The results of this study therefore show that IM olanzapine had a small effect on pulse rate. Hypertension is a risk factor for cardiovascular disease. Furthermore, in the elderly, hypotension is accompanied by lightheadedness, and therefore increases the risk of falls and bone fractures.